"Our study is poised to construct a comprehensive multi-tissue proteomic atlas spanning 50 years of the entire human aging ...

OncoZenge Provides Market and Strategy UpdateOncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced a comprehensive market and strategy update after successfully securing full funding for ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...